Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegavivint - Apollomics/Iterion Therapeutics

Next Previous
Drug Profile

Tegavivint - Apollomics/Iterion Therapeutics

Alternative Names: APL-121; BC-2059; Tegatrabetan - Iterion therapeutics

Latest Information Update: 08 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BetaCat Pharmaceuticals
  • Developer Apollomics; Iterion Therapeutics; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center
  • Class Anthracenes; Antineoplastics; Hydroxylamines; Nitroso compounds; Piperidines; Small molecules; Sulfonamides
  • Mechanism of Action TBL1X protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Fibroma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibroma
  • Phase I/II Adenocarcinoma; Liver cancer; Solid tumours
  • Phase I Osteosarcoma
  • Preclinical Lymphoma
  • No development reported Acute myeloid leukaemia; B-cell lymphoma; Multiple myeloma; Non-small cell lung cancer

Most Recent Events

  • 01 Jun 2026 Interim efficacy, pharmacodynamics and adverse events data from a phase I/II trial in Liver cancer released by Iterion Therapeutics
  • 28 Apr 2026 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in USA (IV)
  • 17 Feb 2026 Phase-I/II clinical trials in Adenocarcinoma (Metastatic disease, Late-stage disease, Second-line therapy or greater, Monotherapy) in USA (IV) (NCT07463599)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top